Henry Schein (NASDAQ:HSIC) Updates FY 2026 Earnings Guidance

Henry Schein (NASDAQ:HSIC) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 5.230-5.370 for the period, compared to the consensus EPS estimate of 5.280. The company issued revenue guidance of $13.6 billion-$13.8 billion, compared to the consensus revenue estimate of $13.5 billion.

Henry Schein Price Performance

HSIC opened at $80.57 on Tuesday. The company has a current ratio of 1.40, a quick ratio of 0.79 and a debt-to-equity ratio of 0.54. The company has a market cap of $9.49 billion, a price-to-earnings ratio of 25.50, a price-to-earnings-growth ratio of 2.37 and a beta of 0.88. The stock has a fifty day simple moving average of $77.43 and a two-hundred day simple moving average of $71.78. Henry Schein has a 12-month low of $60.56 and a 12-month high of $82.80.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.04. Henry Schein had a net margin of 3.02% and a return on equity of 14.76%. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Research analysts predict that Henry Schein will post 4.74 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on HSIC shares. Barrington Research set a $79.00 price target on Henry Schein and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. JPMorgan Chase & Co. increased their target price on Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. Evercore upped their price target on shares of Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 5th. Morgan Stanley raised their price objective on shares of Henry Schein from $55.00 to $58.00 and gave the company an “underweight” rating in a research note on Wednesday, November 5th. Finally, Wall Street Zen raised shares of Henry Schein from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Six research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $78.75.

Institutional Trading of Henry Schein

Large investors have recently made changes to their positions in the stock. Compound Planning Inc. bought a new position in Henry Schein during the fourth quarter valued at approximately $275,000. Corient Private Wealth LLC raised its stake in Henry Schein by 5.4% during the 4th quarter. Corient Private Wealth LLC now owns 37,019 shares of the company’s stock valued at $2,798,000 after buying an additional 1,906 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its holdings in shares of Henry Schein by 7.8% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 4,318 shares of the company’s stock valued at $326,000 after buying an additional 312 shares during the period. State of Tennessee Department of Treasury boosted its stake in shares of Henry Schein by 411.7% in the 4th quarter. State of Tennessee Department of Treasury now owns 75,773 shares of the company’s stock worth $5,719,000 after buying an additional 60,965 shares during the last quarter. Finally, Mackenzie Financial Corp boosted its stake in shares of Henry Schein by 202.4% in the 4th quarter. Mackenzie Financial Corp now owns 10,933 shares of the company’s stock worth $834,000 after buying an additional 7,318 shares during the last quarter. 96.62% of the stock is currently owned by institutional investors.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.